Atea Pharmaceuticals (AVIR) Projected to Post Earnings on Wednesday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.51) per share and revenue of $50.45 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.15. On average, analysts expect Atea Pharmaceuticals to post ($1.99) EPS for the current fiscal year and ($1.48) EPS for the next fiscal year.

Atea Pharmaceuticals Stock Up 3.8%

Shares of NASDAQ:AVIR opened at $4.33 on Wednesday. Atea Pharmaceuticals has a 52-week low of $2.87 and a 52-week high of $6.45. The stock has a market cap of $347.31 million, a price-to-earnings ratio of -2.04 and a beta of 0.76. The business has a 50-day moving average price of $4.99 and a 200-day moving average price of $4.91.

Analyst Ratings Changes

Several brokerages recently weighed in on AVIR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen upgraded shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Morgan Stanley upped their price objective on shares of Atea Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $7.00.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral therapies for serious infectious diseases. The company’s research platform is based on nucleotide and nucleoside prodrug technologies designed to target viral replication.

Atea’s lead product candidate is bemnifosbuvir, formerly known as AT-527, an orally administered antiviral that has been evaluated for the treatment of COVID-19. The company has also investigated bemnifosbuvir and related antiviral approaches for other viral infections, including hepatitis C.